Salk Institute for Biological Studies

Salk Institute for Biological Studies

The Salk Institute for Biological Studies was established in 1960 by Jonas Salk, the developer of the polio vaccine. It functions as an independent nonprofit research institute with an endowment that finances fundamental scientific work. The structure separates research operations from commercial development, relying on the endowment and external grants. The institute allocates roughly 24 percent of its portfolio to private equity alongside public market holdings. Confirmed positions include licensing and patent relationships with BridgeBio Pharma and Ipsen. Geographic exposure centers on the United States with additional research collaborations in Europe. Capital supports both early-stage biotechnology projects and later-stage pharmaceutical partnerships. The organization employs 1,256 people and maintains its headquarters on the original La Jolla campus. Adjacent assets include the Salk Institute Campus and 27 acres of coastal land. No material operational changes to the endowment or board leadership occurred in the last 24 months. The institute's architecture separates the 501(c)(3) research entity from its endowment management, with board oversight provided by trustees drawn from technology and finance backgrounds.